Ozieranski Piotr, Csanádi Marcell, Rickard Emily, Mulinari Shai
Social and Policy Sciences, University of Bath, Bath, UK
Syreon Research Institute, Budapest, Hungary.
BMJ Open. 2020 Sep 19;10(9):e037351. doi: 10.1136/bmjopen-2020-037351.
To examine the under-reporting of pharmaceutical company payments to patient organisations by donors and recipients.
Comparative descriptive analysis of payments disclosed on drug company and charity regulator websites.
UK.
87 donors (drug companies) and 425 recipients (patient organisations) reporting payments in 2012-2016.
Number and value of payments reported by donors and recipients; differences in reported payments from/to the same donors and recipients; payments reported in either dataset but not the other one; agreement between donor-recipient ties established by payments; overlap between donor and recipient lists and, respectively, industry and patient organisation data.
Of 87 donors, 63 (72.4%) reported payments but 84 (96.6%) were mentioned by recipients. Although donors listed 425 recipients, only 200 (47.1%) reported payments. The number and value of payments reported by donors were 259.8% and 163.7% greater than those reported by recipients, respectively. The number of donors with matching payment numbers and values in both datasets were 3.4% and 0.0%, respectively; for recipients these figures were 7.8% and 1.9%. There were 24 and 3 donors missing from industry and patient organisation data during the entire study period, representing 38.1% and 3.6% of those in the respective datasets. The share of donor-recipient ties in which industry and patient organisation data agreed about donors and recipients was 38.9% and 68.4% in each dataset, respectively. Of 63 donors reporting payments, only 3 (4.8%) had their recipient lists fully overlapping with patient organisation data. Of 200 recipients reporting industry funding, 102 (51.0%) had their donor lists fully overlapping with industry data.
Both donors and recipients under-reported payments. Existing donor and recipient disclosure systems cannot manage potential conflicts of interest associated with industry payments. Increased standardisation could limit the under-reporting by each side but only an integrated donor-recipient database could eliminate it.
研究捐赠方和受赠方对制药公司向患者组织支付款项的少报情况。
对制药公司网站和慈善监管机构网站披露的支付情况进行比较描述性分析。
英国。
2012 - 2016年报告支付情况的87家捐赠方（制药公司）和425家受赠方（患者组织）。
捐赠方和受赠方报告的支付款项数量和价值；同一捐赠方与受赠方之间报告的支付差异；在一个数据集中报告但在另一个数据集中未报告的支付；支付所建立的捐赠方 - 受赠方关系的一致性；捐赠方列表与受赠方列表之间的重叠，以及行业数据与患者组织数据之间的重叠。
87家捐赠方中，63家（72.4%）报告了支付情况，但受赠方提到了84家（96.6%）。尽管捐赠方列出了425家受赠方，但只有200家（47.1%）报告了支付情况。捐赠方报告的支付款项数量和价值分别比受赠方报告的多259.8%和163.7%。两个数据集中支付数量和价值匹配的捐赠方比例分别为3.4%和0.0%；受赠方的这些数字分别为7.8%和1.9%。在整个研究期间，行业数据和患者组织数据中分别有24家和3家捐赠方缺失，分别占各自数据集中捐赠方的38.1%和3.6%。在每个数据集中，行业数据和患者组织数据在捐赠方和受赠方方面达成一致的捐赠方 - 受赠方关系比例分别为38.9%和68.4%。在报告支付情况的63家捐赠方中，只有3家（4.8%）的受赠方列表与患者组织数据完全重叠。在报告行业资金的200家受赠方中，102家（51.0%）的捐赠方列表与行业数据完全重叠。
捐赠方和受赠方均少报了支付情况。现有的捐赠方和受赠方披露系统无法管理与行业支付相关的潜在利益冲突。加强标准化可以减少双方的少报情况，但只有一个整合的捐赠方 - 受赠方数据库才能消除这种情况。
